

1 / 104

Fig. 1




Fig. 2





Fig. 3












Fig. 4

4 / 104

Fig. 5a**Fig. 5b****Fig. 5c**

5 / 104

Fig. 6a**Fig. 6b****Fig. 6c**

6 / 104









Fig. 7a**Fig. 7b****Fig. 7c**

Fig. 8a**Fig. 8b****Fig. 8c****Fig. 8d**



Construct Name	Expression mg/L
A - hu<Dig> IgG	18.8
B - <IGF1R-DIG>2321 (disulfide-stabilized)	6.4
C - <Her2-DIG>2321 (disulfide-stabilized)	34.3

8 / 104



Fig. 9a**Fig. 9b****Fig. 9c**

Sample	Σ (mg)	Aggregates
Her2DIGHu2-2320	1	22 %
Her2DIGHu2-2321	31	0 %

9 / 104

Fig. 10a**Fig. 10b**


10 / 104

Fig. 10c**Fig. 10d**


11 / 104

Fig. 10e




RU

**Fig. 10f**

RU




12 / 104


Fig. 11a**Fig. 11b****Fig. 11c**

13 / 104


Fig. 12



14 / 104


Fig. 13a

15 / 104



Fig. 13b

16 / 104



Fig. 14





17 / 104

Fig. 15a**Fig. 15b**


18 / 104

Fig. 15c**Fig. 15d**

19 / 104

Fig. 15e**Fig. 15f**

20 / 104

Fig. 16a

21 / 104






Fig. 17a**Fig. 17b**


Luminescence

above background

**Fig. 17c**


Luminescence

above background




23 / 104

Fig. 18





24 / 104



Fig. 19a**Fig. 19b**

ratio <Her2- Dig>:Doxo	Area (Ex: 488 nm / Em: 540 nm) [mAU*min]
1:0	0
1:0,5	1,1
1:1	2,4
1:2	3,4
1:3	3,3
1:5	4,9
0:1	0



25 / 104

Fig. 20a**Fig. 20b**

26 / 104

Fig. 20c**Fig. 21a**

27 / 104

Fig. 21b**Fig. 21c**

28 / 104

Fig. 22a




Fig. 22b




Fig. 22c






Fig. 23

30 / 104

Fig. 24a**Fig. 24b**

ratio <Her2- Dig>:Dig- Cy5	Area (Ex: 650 nm / Em: 667 nm) [mAU*min]
1:0	2
1:0,5	30
1:1	68
1:2	135
1:3	209
1:5	381
0:1	0

31 / 104



Fig. 25a**Fig. 25b**

Fig. 26a




Fig. 26b




Fig. 27a




Fig. 27b






Fig. 27c




34 / 104



Fig. 28a**Fig. 28b**

35 / 104



Fig. 29





36 / 104

Fig. 30a**Fig. 30b**



37 / 104

Fig. 31a**Fig. 31b**



38 / 104

Fig. 31c**Fig. 31d**

39 / 104

Fig. 31e**Fig. 31f**

40 / 104

Fig. 31g**Fig. 32**

41 / 104



Fig. 33a**Fig. 33b**

Fig. 34a

Fig. 34b

Fig. 34c




Fig. 34d

Fig. 34e

Fig. 34f




Fig. 34g




Fig. 34h



Fig. 34i




Fig. 34j



Fig. 35a




Fig. 35b




Fig. 35c




Fig. 35d



Fig. 35e




Fig. 35f




Fig. 35g




Fig. 35h



46 / 104



Fig. 36a**Fig. 36b**

Fig. 37a







Fig. 37b



48 / 104

Fig. 38a

49 / 104

Fig. 38b

50 / 104







Fig. 38c

Fig. 38d



52 / 104

Fig. 39

53 / 104



Fig. 40a**Fig. 40b**





Fig. 41



Fig. 42



56 / 104

Fig. 43a**Fig. 43b**

57 / 104

Fig. 44a**Fig. 44b**

58 / 104

Fig. 45a

	complex murine Fab DIG-Cy5
Data collection	
Beamline	X06SA (SLS)
Space group	P 42 21 2
Cell dimensions	
a, b, c (Å)	138.103 138.103 123.696
α, β, γ (°)	90.00 90.00 90.00
Wavelength	0.9795
Resolution (Å)	50.0-2.80
Rsym	10.1 (32.1)
I / s	26.38 (9.11)
Completeness (%)	98.1 (95.0)
Redundancy	14.7
Refinement	
Resolution (Å)	46.040 - 2.798
No. reflections (test)	29999 (1534)
Rwork / Rfree	20.340 / 23.12
No. atoms	
Protein	6660
Ligand	2x28
Water	348
B-factor (Å²)	
Protein	23.65
Ligand	16.00
Water	32.29
R.m.s deviations	
Bonds (Å)	0.006
Angles (°)	1.292
Ramachandran	
Core (%)	87.4
Disallowed (%)	0.4

Fig. 45b






Fig. 45c





61 / 104









Fig. 46a

Fig. 46b


63 / 104

Fig. 46c**Fig. 46d**



64 / 104

Fig. 47a



65 / 104

Fig. 47b

66 / 104

Fig. 47c

67 / 104

Fig. 47d**Fig. 47e**

68 / 104

Fig. 47f




Affinity to siRNA-DIG	kd (1/s)	KD (nM)
<IGF1R-DIG> Dig on CH3	9,81E-03	20
<IGF1R-DIG> Dig on Ckappa	9,71E-03	23
<IGF1R-DIG-DIG> hexavalent	9,17E-03	24
Affinity to IGF-1R	kd (1/s)	KD (nM)
<IGF1R-DIG> Dig on CH3	1,09E-03	3
<IGF1R-DIG> Dig on Ckappa	7,99E-03	3
<IGF1R-DIG-DIG> hexavalent	7,64E-03	3

Affinity for DIG-siRNA		kd (1/s)	KD (nM)
<IGF1R-DIG> 2321	5,03E+0	1,17E-02	23
<IGF1R-scFab-DIG> 2321	8,32E+0	1,12E-02	14
<IGF1R-dsFab-DIG> 2321	5,79E+0	7,82E-02	14



Affinity for DIG-siRNA

Capture	Antibody	ka (1/Ms)	kd (1/s)	KD (M)
human VEGFR2-Fc	<VEGFR2(D1F7)-DIG>_001	3.44E+06	6.54E-03	1.09E-09
	<VEGFR2(D1F7)-scFab-DIG>	4.98E+06	6.70E-03	1.35E-09
	<VEGFR2(D1F7)-dsFab-DIG>	2.49E+06	9.68E-03	3.89E-09
mouse VEGFR2-Fc	<VEGFR2(D1F7)-DIG>_001	3.89E+06	6.56E-03	1.69E-09
	<VEGFR2(D1F7)-scFab-DIG>	3.21E+06	8.92E-03	2.78E-09
	<VEGFR2(D1F7)-dsFab-DIG>	2.01E+06	1.14E-02	5.65E-09



69 / 104

Fig. 47g**Fig. 47h****Fig. 47i**




70 / 104

Fig. 47j



71 / 104

Fig. 47k



72 / 104

Fig. 47l**Fig. 47m****Fig. 47n**




73 / 104

Fig. 47o



74 / 104

Fig. 47p



75 / 104

Fig. 47q**Fig. 47r****Fig. 47s**



76 / 104

Fig. 47t


77 / 104

Fig. 47u



78 / 104

Fig. 47v**Fig. 47w****Fig. 47x**



79 / 104

Fig. 48a



80 / 104

Fig. 48b**Fig. 48c**

81 / 104

Fig. 48d**Fig. 48e**


82 / 104

Fig. 49a**Fig. 49b**




83 / 104

Fig. 49c

	Area (Ex: 650 nm / Em: 667 nm) [mAU*min]		
Molar ratio AK: Dig-Cy5	MAb Her-DIG	MAb Her2	MAb IGF-1R
1:0	2	2	1
1:0,5	46	2	1
1:1	94	2	1
1:2	159	2	1
1:3	175	2	1
1:5	177	2	1
0:1	1	0	0

Fig. 49d

84 / 104

Fig. 50a

85 / 104




Fig. 50b

Fig. 51a

cell surface antigen	molecule	format
IGF1-Receptor	<IGF1R-DIG> Fv	scFv/dsscFv; Dig - CH3
IGF1-Receptor	<IGF1R-DIG> Fv	scFv/dsscFv; Dig - Ckappa
IGF1-Receptor	<IGF1R-DIG> Fv	dsscFv; Dig - CH3+Ckappa
IGF1-Receptor	<IGF1R-DIG> Fab	scFab; Dig - CH3
IGF1-Receptor	<IGF1R-DIG> Fab	dsscFab; Dig - CH3
VEGF-Receptor 2	<VEGFR2-DIG> Fv	scFv/dsscFv; Dig - CH3
VEGF-Receptor 2	<VEGFR2-DIG> Fab	scFab; Dig - CH3
VEGF-Receptor 2	<VEGFR2-DIG> Fab	dsscFab; Dig - CH3
CD33	<CD33-DIG> Fab	dsscFab; Dig - CH3
CD33	<CD33-DIG> Fv	scFv/dsscFv; Dig - CH3
LeY carbohydrate	<LeY-DIG> Fab	dsscFab; Dig - CH3
LeY carbohydrate	<LeY-DIG> Fv	scFv/dsscFv; Dig - CH3
CD22	<CD22-DIG> Fv	dsscFv; Dig - CH3
Her2	<Her2-DIG> Fv	dsscFv; Dig - CH3
CDCP1	<CDCP1-DIG> Fv	dsscFv; Dig - CH3



Fig. 51b

88 / 104

Fig. 51c

Capture	Antibody	ka (1/Ms)	kd (1/s)	KD (M)
human VEGFR2-Fc	<VEGFR2(D1F7)-DIG>_001	3.44E+06	6.54E-03	1.90E-09
	<VEGFR2(D1F7)-scFab-DIG>	4.98E+06	6.70E-03	1.35E-09
	<VEGFR2(D1F7)-dsFab-DIG>	2.49E+06	9.68E-03	3.89E-09
mouse VEGFR2-Fc	<VEGFR2(D1F7)-DIG>_001	3.89E+06	6.56E-03	1.69E-09
	<VEGFR2(D1F7)-scFab-DIG>	3.21E+06	8.92E-03	2.78E-09
	<VEGFR2(D1F7)-dsFab-DIG>	2.01E+06	1.14E-02	5.65E-09

89 / 104

Fig. 51d**Fig. 51e**

90 / 104




Fig. 51f**Fig. 51g**

Fig. 51h

	ka (1/Ms)	kd (1/s)	KD (nM)
CDCP1-ECD	2.02E+05	1.32E-03	7
	2.02E+05	1.60E-03	8
DIG-siRNA	4.37E+05	0.0097	22
	5.54E+05	0.011	20



92 / 104



Fig. 52a**Fig. 52b**

Fig. 52c

EG5/GAPDH mRNA level [%]







Fig. 53a**Fig. 53b**


95 / 104

Fig. 53c

AHA1/GAPDH [% of control]

**Fig. 53d**



AHA1/GAPDH [% of control]



96 / 104

Fig. 53e


AHA1/GAPDH ration [% of control]

**Fig. 53f**Targeting specificity factor
[IC40 LeY/CD22]


97 / 104

Fig. 54a

molar mass (g/mol)

**Fig. 54b**


molar mass (g/mol)



98 / 104

Fig. 54c

hydrodynamic radius (nm)

**Fig. 54d**

hydrodynamic radius (nm)




Fig. 55a








Fig. 55b**Fig. 55c****Fig. 55d**

101 / 104



Fig. 56a

Fig. 56b

103 / 104


Fig. 56c

Fig. 57

